Cat. No.
MABL-3728
Application
therapeutic, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
LY2062430 (Solanezumab, hu266)
From
Recombinant Antibody
Specificity
This antibody recognizes amino acids 13-28 of amyloid beta and only recognized soluble form of the amyloid beta peptide. It functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis.
Alternative Names
APP; Aβ peptide; Abeta; A-beta; Aβ; Aβ42; amyloid beta peptide; Alzheimer disease amyloid protein; Beta-amyloid precursor protein; Protease nexin-II; humanized m266.2
UniProt
P05067
Immunogen
The parental mouse antibody 266 was generated by immunization of mice with a peptide composed of residues 13-28 of human Aβ peptide. The original humanized version of the antibody was generated by grafting CDRs of the mouse antibody onto human framework regions.
Application Notes
The human IgG1 version of this antibody binds amyloid beta peptide Aβ1-42 with a binding affinity of Kd= 4pM in an in vitro BIAcore assay. The binding characterization of this antibody towards Aβ1-42-BSA conjugate was done using ELISA (US8591894). A study in patients with Alzheimer's disease (AD) suggested that a single dose of solanezumab was generally well tolerated, except that mild self-limited symptoms consistent with infusion reactions occurred in few patients when higher doses are given. A dose-dependent change in plasma and CSF Abeta was also observed (PMID: 20375655). The original mouse antibody 266 slowed Aβ accumulation in the brain but failed to deplete Aβ plaques in animal studies (PMID: 11438712). This humanized antibody is likely to have impeded the efflux of soluble Aβ from the brain in patients owing to the formation of Aβ–antibody complexes in the brain interstitial fluid and cerebrospinal fluid, as suggested from animal studies (PMID: 24638135). Phase 1 and 2 studies of solanezumab revealed evidence of target engagement by dose-dependent increases in plasma and CSF total Aβ (PMID: 20375655; 22672770).
Antibody First Published
Siemers et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. PMID:20375655
Note on publication
This study evaluates the safety and tolerance of solanezumab after single administration in patients with Alzheimer's disease.
Size
209 μg Purified antibody.
Concentration
110 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 409.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 129⁰C.
![Anti-VEGF [Bevacizumab] (MABL-](/public/static/common/images/not_adv.jpg)
